Profound Medical Corp

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The firm's platforms offer clinicians and patients incision-free alternatives to current standards of care, which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Profound Medical Corp reports revenue growth and eyes expansion opportunities

Profound Medical Corp's Q4 2022 performance reflects revenue growth driven by recurring revenue and progress in key trials and applications.
While facing financial challenges and capacity constraints, the company's strengths lie in the growing adoption of TULSA-PRO and AI software innovations.
Opportunities for growth include pending trial results, AI software value proposition, and expansion plans in key states, positioning the company for future success.

Profound Medical Corp reports revenue growth and expansion opportunities

Profound Medical Corp shows promising revenue growth and recurring revenue increase in Q1 2023, driven by the success of TulsaPro and Sonalleve platforms. While facing challenges in managing expenses and reducing backlog, the company is focused on expanding installations and preparing for reimbursement to drive future growth.

Profound Medical Corp reports revenue growth amidst widened net loss

Profound Medical Corp reported strong revenue growth in Q2 2023, driven by their innovative treatment technologies.
While facing challenges with a widened net loss, the company's focus on operational efficiency and market expansion presents growth opportunities.
Future prospects include expanding the install base, improving margins, and leveraging AI technology to drive profitability and market reach.

Profound Medical Corp reports revenue growth amidst profitability challenges

Profound Medical Corp's Q3 2023 performance showed revenue growth and strong cash reserves, but challenges persist in managing expenses and achieving profitability.
The company's strengths include recurring revenue growth, strategic partnerships, and innovative developments in AI applications for medical procedures.
Addressing operational challenges and seizing opportunities in market expansion and technology advancements will be crucial for future success.

Profound Medical Corp reports robust revenue growth and strategic focus

Profound Medical Corp's Q4 2023 performance showed strong revenue growth and strategic focus on TULSA's market adoption and innovation.
While facing challenges with patient reimbursement and payment models, the company aims to capitalize on opportunities for expansion and increased utilization.
By emphasizing customer retention, technology advancement, and market awareness, Profound Medical Corp positions itself for sustained growth and success in the prostate cancer treatment market.

Profound Medical Corp reports Q1 growth, eyes TULSA technology opportunities

Profound Medical Corp's Q1 2024 performance reflects a mix of revenue growth and operational improvements.
The company's focus on innovative TULSA technology and strategic collaborations positions it for future success.
While facing financial challenges and high operating expenses, Profound's growth outlook remains positive.
Navigating reimbursement rates and optimizing revenue streams are key priorities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Profound Medical Corp. engages in developing, manufacturing, and marketing of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. Its platforms offer clinicians and patients incision-free alternatives to current standards of care, which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, Canada.

TORONTO, June 16, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will participate in a virtual panel discussion on Focused Ultrasound hosted by Joshua Jennings, M.D., Managing Director, Health Care - Medical Supplies & Devices, at Cowen's 7th Annual FutureHealth Conference on Thursday, June 23, 2022 at 9:55 a.m. Eastern Time.

Profound Medical to Participate in the Cowen 7th Annual FutureHealth Conference

TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2022 Jefferies Global Healthcare Conference in New York City on Thursday, June 9, 2022 at 4:30 p.m. Eastern Time.

Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference

TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its insiders, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today provided the following clarifications.

Profound Medical Clarifies Recent Insider Buying

Activities Highlighting Profound's Ground-Breaking Technology Included a Semi-Live TULSA Procedure Performed by UT Southwestern's Dr. Kenneth A. Goldberg During Meeting's Plenary Session Activities Highlighting Profound's Ground-Breaking Technology Included a Semi-Live TULSA Procedure Performed by UT Southwestern's Dr. Kenneth A. Goldberg During Meeting's Plenary Session

TULSA-PRO® Was Front and Center at AUA2022

Profound Medical Corp. (NASDAQ:PROF ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Dr. Arun Menawat – Chief Executive Officer and Chairman of the Board Rashed Dewan – Chief Financial Officer Stephen Kilmer – Investor Relations Conference Call Participants Rahul Sarugaser – Raymond James Frank Takkinen – Lake Street Capital Markets Josh Jeggings – Cowen and Company Scott McAuley – Paradigm Capital Brian Gagnon – Gagnon Securities Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter 2022 Financial Results Conference Call.

Profound Medical Corp. (PROF) CEO Dr. Arun Menawat on Q1 2022 Results - Earnings Call Transcript

Profound Medical (PROF) delivered earnings and revenue surprises of 11.11% and 9.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q1 Loss, Lags Revenue Estimates

TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2022. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Profound Medical Announces First Quarter 2022 Financial Results

TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 2:00 p.m. Eastern Time at the Metro Toronto Convention Centre.

Profound Medical to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2022 financial results after market close on Monday, May 9, 2022.

Profound Medical to Release First Quarter 2022 Financial Results on May 9 – Conference Call to Follow

Profound Medical Corp. (PROF) CEO Dr. Arun Menawat on Q4 2021 Results - Earnings Call Transcript

TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2021. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results

TORONTO, March 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in March.

Profound Medical to Participate in March Investor Conferences

Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Profound Medical (PROF) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

TORONTO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2021 financial results after market close on Thursday, March 3, 2022.

Profound Medical to Release Fourth Quarter and Full Year 2021 Financial Results on March 3 – Conference Call to Follow

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, to be held virtually February 15-17, 2022.

Profound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference

TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 ‘ CAPTAIN ' trial.

Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy

TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of accomplished global medical device industry veteran, Kenneth Knudson, as Chief Commercial Officer. Mr. Knudson's mandate will be leading Profound's worldwide sales, marketing and reimbursement activities.

Kenneth Knudson Joins Profound Medical as Chief Commercial Officer

Profound Medical Corp. (PROF) CEO Arun Menawat on Q3 2021 Results - Earnings Call Transcript

TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2021.

Profound Medical Announces Third Quarter 2021 Financial Results

TORONTO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in two investor conferences in November.

Profound Medical to Participate in November Virtual Investor Conferences

Will Profound Medical (PROF) Report Negative Earnings Next Week? What You Should Know

TORONTO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2021 financial results after market close on Thursday, November 4, 2021.

Profound Medical to Release Third Quarter 2021 Financial Results on November 4 – Conference Call to Follow

TORONTO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announce today that management will participate in two investor conferences in September.

Profound Medical to Participate in September Virtual Investor Conferences

Profound Medical Corp.'s (PROF) CEO Dr. Arun Menawat on Q2 2021 Results - Earnings Call Transcript

PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -34.62% and 15.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Profound Medical Corp Stock (PROF)